The University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.
Amir Goldkorn, MD
Advertisement
Articles by Amir Goldkorn, MD
Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPC
Published: | Updated:
Baseline CTC counts were shown to be strong indicators for subsequent therapy response and 2-year progression-free survival.
Advertisement
Latest Updated Articles
Amir Goldkorn, MD Talks Next Steps for SWOG 1216 TrialPublished: July 2nd 2020 | Updated: July 6th 2022
Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPCPublished: May 30th 2020 | Updated: July 6th 2022
Advertisement
Advertisement
Trending on CancerNetwork
1
Adding SBRT to Ipilimumab/Nivolumab Does Not Improve PFS in Advanced RCC
2
Lessons From the Withdrawal of Atezolizumab in Metastatic TNBC
3
Molecular Interception: Discussing the Future of Surgery in Breast Cancer
4
Examining Pembrolizumab Combo Safety in High-Risk Prostate Cancer
5